



Supplementary figures.



Supplementary Figure 1. DRα1-mMOG-35-55 treats clinical EAE in DR*1502-Tg mice.

DR*1502-Tg mice with human MOG-35-55-induced EAE were treated after disease onset at a clinical score of ≥ 2 with DRα1-mMOG-35-55 (100 μ g, daily x 5, black arrows) or Vehicle. Mean clinical EAE daily disease scores (left) and cumulative disease index scores (right) are shown. * $p < 0.05$, ** $p < 0.01$. Daily mean scores were analyzed by Mann Whitney U and mean CDI by Student's t-test.



Supplementary Figure 2. DRα1-mMOG-35-55 treatment increases the frequency of CD11b⁺CD206⁺ in spinal cords of EAE mice. (a) Frequency of CD206⁺ on CD11b⁺CD45^{hi} cells from spinal cords of DRα1-mMOG-35-55- (n=6) vs. Vehicle-treated (n=6) DR*1501-Tg mice with EAE. (b) Splenocytes from naïve DR*1501-Tg mice (n=4) were treated with 10ng/ml LPS, 100ng/ml recombinant MIF and 25μg/ml DRα1-mMOG-35-55 for 24 hr. Frequency of CD206⁺ on CD11b⁺F4/80⁺ cells was evaluated by flow cytometry. Data are presented as mean ± SD. * p<0.05, (a) Student's t-test. (b) One way ANOVA with Tukey post-test.